J
J. Andrew Bird
Researcher at University of Texas Southwestern Medical Center
Publications - 92
Citations - 3105
J. Andrew Bird is an academic researcher from University of Texas Southwestern Medical Center. The author has contributed to research in topics: Food allergy & Peanut allergy. The author has an hindex of 22, co-authored 78 publications receiving 2474 citations. Previous affiliations of J. Andrew Bird include University of Texas at Dallas & Baylor College of Medicine.
Papers
More filters
Journal ArticleDOI
AR101 Oral Immunotherapy for Peanut Allergy
Brian P. Vickery,Andrea Vereda,Thomas B. Casale,Kirsten Beyer,George Du Toit,Jonathan O'b Hourihane,Stacie M. Jones,Stacie M. Jones,Wayne G. Shreffler,Annette Marcantonio,Rezi Zawadzki,Lawrence Sher,W. Carr,Stanley Fineman,Leon Greos,Rima Rachid,M Dolores Ibáñez,Stephen A. Tilles,Amal Assa'ad,Caroline Nilsson,Ned Rupp,Michael J Welch,Gordon Sussman,Sharon Chinthrajah,Katharina Blumchen,Ellen Sher,Jonathan M. Spergel,Frederick E Leickly,Stefan Zielen,Julie Wang,Georgiana M Sanders,Robert A. Wood,Amarjit Cheema,Carsten Bindslev-Jensen,Stephanie A. Leonard,Rita Kachru,Douglas T Johnston,Frank C Hampel,Edwin H. Kim,Aikaterini Anagnostou,Jacqueline A. Pongracic,Moshe Ben-Shoshan,Hemant P Sharma,Allan Stillerman,Hugh H Windom,William H. Yang,Antonella Muraro,José Manuel Zubeldia,Vibha Sharma,Morna J. Dorsey,Hey Chong,Jason A. Ohayon,J. Andrew Bird,Tara F. Carr,Dareen Siri,Montserrat Fernandez-Rivas,David K Jeong,David Fleischer,Jay A. Lieberman,Anthony E.J. Dubois,Marina Tsoumani,Christina E. Ciaccio,Jay M. Portnoy,Lyndon E Mansfield,Stephen B Fritz,Bruce J. Lanser,Jonathan Matz,Hanneke N G Oude Elberink,Pooja Varshney,Stephen G Dilly,Daniel C. Adelman,A. Wesley Burks +71 more
TL;DR: Treatment with AR101 resulted in higher doses of peanut protein that could be ingested without dose‐limiting symptoms and in lower symptom severity during peanut exposure at the exit food challenge than placebo, in this phase 3 trial of oral immunotherapy in children and adolescents who were highly allergic to peanut.
Journal ArticleDOI
Mepolizumab for Severe Eosinophilic Asthma (DREAM): A Multicentre, Double-Blind, Placebo-Controlled Trial
TL;DR: To elucidate the efficacy, safety, and patient characteristics of responsiveness to mepolizumab (a humanized monoclonal antibody against interleukin 5), a large number of patients with severe, eosinophilic asthma were enrolled in 81 multinational centers.
Journal ArticleDOI
Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization.
Edwin H. Kim,J. Andrew Bird,Michael D. Kulis,Susan Laubach,Laurent Pons,Wayne G. Shreffler,Pamela H. Steele,J. Kamilaris,Brian P. Vickery,A. Wesley Burks +9 more
TL;DR: This paper investigated the safety, clinical effectiveness, and immunologic changes with Sublingual Immunotherapy (SLIT) in children with peanut allergy and found that the treatment group safely ingested 20 times more peanut protein than the placebo group during a double-blind, placebo-controlled food challenge.
Journal ArticleDOI
Effect of Epicutaneous Immunotherapy vs Placebo on Reaction to Peanut Protein Ingestion among Children with Peanut Allergy: The PEPITES Randomized Clinical Trial
David Fleischer,Matthew Greenhawt,Gordon Sussman,Philippe Bégin,Anna Nowak-Wegrzyn,Daniel Petroni,Kirsten Beyer,Terri F. Brown-Whitehorn,Jacques Hébert,Jonathan O'b Hourihane,Dianne E. Campbell,Stephanie A. Leonard,R. Sharon Chinthrajah,Jacqueline A. Pongracic,Stacie M. Jones,Lars Lange,Hey Chong,Todd D. Green,Todd D. Green,Robert J. Wood,Amarjit Cheema,Susan L. Prescott,Pete Smith,William H. Yang,Edmond S. Chan,Aideen Byrne,Amal Assa'ad,J. Andrew Bird,Edwin H. Kim,Lynda C. Schneider,Carla M. Davis,Bruce J. Lanser,Romain Lambert,Wayne G. Shreffler +33 more
TL;DR: Among peanut-allergic children aged 4 to 11 years, the percentage difference in responders at 12 months with the 250-&mgr;g peanut-patch therapy vs placebo was 21.7% and was statistically significant, but did not meet the prespecified lower bound of the confidence interval criterion for a positive trial result.
Journal ArticleDOI
Adverse reactions during peanut oral immunotherapy home dosing
Pooja Varshney,Pamela H. Steele,Brian P. Vickery,J. Andrew Bird,A. Thyagarajan,Amy M. Scurlock,Tamara T. Perry,Stacie M. Jones,A. Wesley Burks +8 more
TL;DR: It is observed that dosing during febrile illnesses has been associated with systemic reactions to previously tolerated peanut OIT doses, and subjects are advised to resume dosing at home if fewer than three doses are missed, and to withholding OIT during acute illnesses.